Does NIVOLUMAB Cause Immune-mediated hypophysitis? 171 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 171 reports of Immune-mediated hypophysitis have been filed in association with NIVOLUMAB (OPDIVO). This represents 0.2% of all adverse event reports for NIVOLUMAB.
171
Reports of Immune-mediated hypophysitis with NIVOLUMAB
0.2%
of all NIVOLUMAB reports
9
Deaths
101
Hospitalizations
How Dangerous Is Immune-mediated hypophysitis From NIVOLUMAB?
Of the 171 reports, 9 (5.3%) resulted in death, 101 (59.1%) required hospitalization, and 33 (19.3%) were considered life-threatening.
Is Immune-mediated hypophysitis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NIVOLUMAB. However, 171 reports have been filed with the FAERS database.
What Other Side Effects Does NIVOLUMAB Cause?
Death (11,216)
Malignant neoplasm progression (9,363)
Off label use (5,208)
Diarrhoea (4,692)
Fatigue (3,709)
Pyrexia (3,454)
Intentional product use issue (3,297)
Rash (2,816)
Nausea (2,805)
Decreased appetite (2,619)
What Other Drugs Cause Immune-mediated hypophysitis?
PEMBROLIZUMAB (137)
IPILIMUMAB (135)
CARBOPLATIN (59)
PACLITAXEL (42)
CYCLOPHOSPHAMIDE (33)
EPIRUBICIN (23)
DURVALUMAB (14)
BEVACIZUMAB (12)
DOXORUBICIN (11)
LENVATINIB (10)
Which NIVOLUMAB Alternatives Have Lower Immune-mediated hypophysitis Risk?
NIVOLUMAB vs NIVOLUMAB\RELATLIMAB-RMBW
NIVOLUMAB vs NIZATIDINE
NIVOLUMAB vs NOMEGESTROL
NIVOLUMAB vs NORDAZEPAM
NIVOLUMAB vs NOREPINEPHRINE